BioSpace News Archive

Trobix Bio, a company utilizing CRISPR, phage, and synthetic biology technologies to develop advanced precision microbiome oncology therapeutics, announced the successful closing of a US $3 million equity investment by Chartered Group, a well-established global private investment group.

In cooperation with Perimed AB, researchers from the Department of Biomedical Engineering at Linköping University, Sweden, have developed a new method for imaging microvascular blood flow in video-rate that enables new aspects of evaluating the vital transport of oxygen to cells.

Takeda announced that its Board of Directors decided that it will propose a new candidate for independent external director at the 147th Ordinary Meeting of Shareholders on June 28th, 2023.

AlzeCure Pharma AB, a pharmaceutical company that develops a broad portfolio of small molecule candidate drugs for diseases affecting the central nervous system, with projects in both Alzheimer’s disease and pain, announced that the company’s presentation at the Alzheimer’s conference AD/PD 2023 is now available in its entirety on the company’s website.

The shareholders in Swedish Orphan Biovitrum AB Reg. No. 556038-9321, are hereby summoned to the Annual General Meeting, to be held on Tuesday, 9 May 2023 at 15.00 at IVA Konferenscenter, Grev Turegatan 16, Stockholm, Sweden.

DXVX announces that its affiliated company Oxford Vacmedix has completed Phase 1a trial of cancer vaccine and plans to proceed Phase 1b trial of OVM-200.

European biotech AlgoTx, a clinical stage innovator in complex pain, announces that the U.S. Food and Drug Administration has cleared the Investigational New Drug Application for its Phase 2 first-in-class candidate ATX01 in the treatment of erythromelalgia.

FogPharma®, a biopharmaceutical company committed to transforming the lives of patients through a new precision medicine approach widely applicable to important and challenging intracellular targets, announced that Mathai Mammen, M.D., Ph.D., will join the company as chairman, president and chief executive officer.

Insulet Corporation, the global leader in tubeless insulin pump technology with its Omnipod® brand of products, announced plans to release its financial results for the first quarter of 2023 on May 4, 2023 after the close of the financial markets.

LimFlow SA announced that results from the PROMISE II U.S. pivotal trial were published.